Alcohol reduction combined with smoking cessation may decrease weight gain and relapse.
Health state descriptions for stable schizophrenia, extra pyramidal symptoms (EPS), hyperprolactinemia, diabetes, weight gain and relapse were developed based on a review of the literature and expert opinion.
A possible explanation for this is that it is entirely possible that tumour growth rate may be slowed by neoadjuvant therapy (as measured, for example, by a reduction in proliferation factor Ki67) without a formal clinical response being achieved but with a consequent gain in relapse free survival.
Furthermore, among the 238 women with advanced stage disease, of which 220 women with no residual tumour at the end of second-look surgery (absent or surgical converted to absent), lymphadenectomy was not associated with a survival gain (HR for relapse: 1.06; 95% CI=0.77 1.45; P=0.73 and HR for death: 0.96; 95% CI=0.66 1.40; P=0.83).
We assumed that interventions would be repeated in the third, sixth and tenth year after the initial intervention, and that despite this 50% of participants achieving change at follow-up would subsequently relapse gaining no health benefits.
Other withdrawal symptoms (weight gain and depression) triggered relapse much later.
However, data are conflicting for the association between weight gain and probability of relapse.
There are many barriers to successful cessation of smoking including concern over weight gain, the fear of relapse, and general lack of support.
In a sensitivity analysis the number of patients who relapse (and gain no health improvement) was varied between 25% and 75%.
After an initial weight reduction in both groups, patients in the relapse group gained weight in contrast to patients in the non-relapse group who maintained weight or gained further weight loss (p=0.013).
